The global incidence of bladder cancer is more than half a million diagnoses each year.
Bladder cancer can be categorized into non-muscle-invasive bladder cancer (NMIBC) …

Understanding the molecular determinants that underpin the clinical heterogeneity of non-
muscle-invasive bladder cancer (NMIBC) is essential for prognostication and therapy …

Within the heterogeneous population of patients with bacillus Calmette‐Guérin failure, there
are clear differences in prognosis and therapy with regard to the timeline when bacillus …

Background The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-
PB™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in …

Introduction Bladder microbiota dysbiosis has been associated with several urological
disorders. However, dysbiosis markers in bladder cancer have not been identified and little …

Advances in the field of cancer biology and molecular techniques have led to a better
understanding of the molecular underpinnings driving cancer development and outcomes …

Almost 50 years after first use, instillation therapy with attenuated strains of Mycobacterium
bovis (Bacillus Calmette-Guérin, BCG) is still the gold standard in the treatment of high-risk …

Immunotherapy has recently been incorporated into the treatment guidelines for metastatic
urothelial carcinoma. Nevertheless, the role of prognostic and predictive biomarkers in this …

The 4th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in
conjunction with the 42nd Annual Congress of the Société Internationale d'Urologie, was …

Immunotherapy has recently been incorporated into the treatment guidelines for metastatic
urothelial carcinoma. Nevertheless, the role of prognostic and predictive biomarkers in this …